Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Drug Resistance

  Free Subscription

Articles published in N Engl J Med

Retrieve available abstracts of 48 articles:
HTML format

Single Articles

    May 2021
  1. HOBERMAN A, Preciado D, Paradise JL, Chi DH, et al
    Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media.
    N Engl J Med. 2021;384:1789-1799.
    PubMed     Abstract available

    April 2021
  2. WANG GL, Wang ZY, Duan LJ, Meng QC, et al
    Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
    N Engl J Med. 2021 Apr 6. doi: 10.1056/NEJMc2103022.

    February 2021
  3. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.
    N Engl J Med. 2021;384:e40.

    November 2020
  4. DOAN T, Worden L, Hinterwirth A, Arzika AM, et al
    Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.
    N Engl J Med. 2020;383:1941-1950.
    PubMed     Abstract available

    August 2020
  5. KADRI SS, Boucher HW
    U.S. Efforts to Curb Antibiotic Resistance - Are We Saving Lives?
    N Engl J Med. 2020;383:806-808.

  6. MASHE T, Domman D, Tarupiwa A, Manangazira P, et al
    Highly Resistant Cholera Outbreak Strain in Zimbabwe.
    N Engl J Med. 2020;383:687-689.

    July 2020
  7. JERNIGAN JA, McDonald LC, Baggs J
    Multidrug-Resistant Infections in U.S. Hospitals. Reply.
    N Engl J Med. 2020;383:94.

  8. LE GUERN R, Loiez C, Wallet F
    Multidrug-Resistant Infections in U.S. Hospitals.
    N Engl J Med. 2020;383:93-94.

    April 2020
  9. MELLON G, Turbett SE, Worby C, Oliver E, et al
    Acquisition of Antibiotic-Resistant Bacteria by U.S. International Travelers.
    N Engl J Med. 2020;382:1372-1374.

  10. FANG FC, Schooley RT
    Antimicrobial Resistance - The Glass Is Half Full.
    N Engl J Med. 2020;382:1363-1365.

  11. JERNIGAN JA, Hatfield KM, Wolford H, Nelson RE, et al
    Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.
    N Engl J Med. 2020;382:1309-1319.
    PubMed     Abstract available

  12. ZAHEEN A, Bloom BR
    Tuberculosis in 2020 - New Approaches to a Continuing Global Health Crisis.
    N Engl J Med. 2020;382:e26.

    March 2020
  13. KOZAL M, Aberg J, Pialoux G, Cahn P, et al
    Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    N Engl J Med. 2020;382:1232-1243.
    PubMed     Abstract available

  14. SWINDELLS S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, et al
    Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1904398.
    PubMed     Abstract available

  15. ORKIN C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, et al
    Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1909512.
    PubMed     Abstract available

    December 2019
  16. WILLIAMSON D, Ingle D, Howden B
    Extensively Drug-Resistant Shigellosis in Australia among Men Who Have Sex with Men.
    N Engl J Med. 2019;381:2477-2479.

    November 2019
  17. LIETMAN TM, Doan T, Keenan JD
    Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I. Reply.
    N Engl J Med. 2019;381:2184-2185.

    Macrolide Resistance and Longer-Term Assessment of Azithromycin in MORDOR I.
    N Engl J Med. 2019;381:2184.

  19. DEFILIPP Z, Bloom PP, Torres Soto M, Mansour MK, et al
    Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.
    N Engl J Med. 2019;381:2043-2050.
    PubMed     Abstract available

    September 2019
  20. NUNN AJ, Phillips PPJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
    N Engl J Med. 2019;381:e22.

  21. TORNHEIM JA, Udwadia ZF, Gupta A
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.

  22. MCCAW ZR, Meng Z, Wei LJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.

    August 2019
  23. LUBKE N, Jensen B, Huttig F, Feldt T, et al
    Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.
    N Engl J Med. 2019;381:887-889.

  24. NIELSEN TB, Brass EP, Gilbert DN, Bartlett JG, et al
    Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?
    N Engl J Med. 2019;381:503-505.

    June 2019
  25. DOAN T, Arzika AM, Hinterwirth A, Maliki R, et al
    Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
    N Engl J Med. 2019;380:2271-2273.

    April 2019
  26. WOJCIECHOWSKI D, Gandhi RT, Rosales IA
    Case 11-2019: A 49-Year-Old Man with HIV Infection and Chronic Kidney Disease.
    N Engl J Med. 2019;380:1464-1472.

    March 2019
  27. CROWE SE
    Helicobacter pylori Infection.
    N Engl J Med. 2019;380:1158-1165.

  28. NUNN AJ, Phillips PPJ, Meredith SK, Chiang CY, et al
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMoa1811867.
    PubMed     Abstract available

    A Short Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMe1902904.

    February 2019
  30. MCKINNELL JA, Dwyer JP, Talbot GH, Connolly LE, et al
    Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.
    N Engl J Med. 2019;380:791-793.

  31. WAGENLEHNER FME, Cloutier DJ, Komirenko AS, Cebrik DS, et al
    Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    N Engl J Med. 2019;380:729-740.
    PubMed     Abstract available

  32. O'RIORDAN W, Green S, Overcash JS, Puljiz I, et al
    Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
    N Engl J Med. 2019;380:528-538.
    PubMed     Abstract available

    November 2018
  33. BLANK S, Daskalakis DC
    Neisseria gonorrhoeae - Rising Infection Rates, Dwindling Treatment Options.
    N Engl J Med. 2018;379:1795-1797.

    October 2018
  34. ANDREWS JR, Qamar FN, Charles RC, Ryan ET, et al
    Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?
    N Engl J Med. 2018;379:1493-1495.

    September 2018

  35. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMoa1800474.
    PubMed     Abstract available

    August 2018
  36. COLANGELI R, Jedrey H, Kim S, Connell R, et al
    Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    N Engl J Med. 2018;379:823-833.
    PubMed     Abstract available

  37. EMU B, Fessel J, Schrader S, Kumar P, et al
    Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    N Engl J Med. 2018;379:645-654.
    PubMed     Abstract available

  38. SHEIKH V, Murray JS, Sherwat A
    Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.
    N Engl J Med. 2018;379:605-607.

    April 2018
  39. KEENAN JD, Bailey RL, West SK, Arzika AM, et al
    Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.
    N Engl J Med. 2018;378:1583-1592.
    PubMed     Abstract available

    March 2018
  40. GOTTLIEB GS, Raugi DN, Smith RA
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874-5.

  41. BERTAGNOLIO S, Jordan MR, Doherty M
    HIV Drug Resistance.
    N Engl J Med. 2018;378:874.

  42. INZAULE SC, Rinke de Wit TF, Hamers RL
    HIV Drug Resistance.
    N Engl J Med. 2018;378:873-4.

  43. HIV Drug Resistance.
    N Engl J Med. 2018;378:873-875.

    October 2017
  44. BEYRER C, Pozniak A
    HIV Drug Resistance - An Emerging Threat to Epidemic Control.
    N Engl J Med. 2017;377:1605-1607.

    September 2017
    Game of TOR - The Target of Rapamycin Rules Four Kingdoms.
    N Engl J Med. 2017;377:1297-9.

  46. XIE YL, Chakravorty S, Armstrong DT, Hall SL, et al
    Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:1043-1054.
    PubMed     Abstract available

    June 2017
  47. RUBIN EJ
    Reviving a Drug for Tuberculosis?
    N Engl J Med. 2017;376:2292-2294.

  48. BOURLIERE M, Gordon SC, Flamm SL, Cooper CL, et al
    Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    N Engl J Med. 2017;376:2134-2146.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.